Latest article
U.S. FDA declines to approve Provention Bio’s diabetes drug
(Reuters) - The U.S. Food and Drug Administration on Tuesday rejected Prevention Bio Inc.'s approval of the experimental diabetes drug teplizumab, citing insufficient data,...
